|
|
 |
||
 |
 |
 |
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
| Division of Endocrinology and Diabetes | |
| Head of Division: Dr. C C Chow, Consultant Physician and Chief of Service | |
| Members: | |
| Professor
Clive Cockram, Professor of Medicine Professor Juliana CN Chan, Professor of Medicine and Therapeutics Dr. Peter CY Tong, Associate Professor Dr. WY So, Associate Consultant Dr. Alice PS Kong, Associate Professor Dr. WB Chan, Honorary Assistant Professor Dr. Maggie CY Ng, Assistant Professor Dr. Hailu Zhou, Research Assistant Professor Dr. Angela Cheng, Clinical Officer Dr. Li-Zhong Liu, Research Associate Dr. XL Yang, Post-doctoral fellow |
|
| Honorary Member: | |
| Dr. Norman N Chan, Dr. KF Lee, Dr. June KY Li, Dr. Matthew KW Lo, Dr. Gary TC Ko, Dr. Vincent TF Yeung | |
| Endocrine Fellows: | |
| Dr. Ronald Ma, Dr. Risa Ozaki, Dr. CY Yeung | |
| Research Students (PhD): | |
| Mr. Stanley Cheung, Mr. Vincent Lam, Mr. TK Leung, Ms. Sui Yi | |
| Technologists | |
| Mr. Stanley Ho (Senior technician), Mr. Vincent Lam (technician), Mr. Stanley Cheung (research assistant), Ms. Patty Tse (research assistant) | |
| The Prince of Wales Hospital Diabetes & Endocrine Centre | |
| Diabetes Educators: Ms. Rebecca Wong, Ms. Kit-Man Loo, Ms. Theresa Yeung, Ms Maggie Lau, Ms. Tammy So | |
| Clerical officer: Mr. Kevin Yu | |
| Contact
Person: Ms. Rebecca Wong Tel no.: 852 2632 2876 Fax no.: 852 2637 3852 |
|
| The Hong Kong Foundation for Research and Development in Diabetes (HKFRDD) | |
| Founding Chairman: Professor Juliana CN Chan | |
| Secretariat:
Ms Charmaine Lee Tel no.: 852 2632 3130 Fax no.: 852 26373929 Website: www.hkfrdd.org.hk |
|
| The missions of HKFRDD are: | |
| 1. | Establishment of scholarships and awards for both clinical and basic scientists in Hong Kong and Mainland China to conduct research in diabetes and related diseases. |
| 2. | Collaboration with leading academic institutions and other international organisations to develop research and development programs in diabetes and related diseases, including the scientific use of Traditional Chinese Medicine. |
| 3. | Organisation of scientific meetings to promote academic exchanges between local and overseas investigators. |
| 4. | Organisaton of professional courses (certificate, diploma and MSc) for health care workers for continuous professional and medical training. |
| 5. | Development of evidence-based disease management programs and evaluation of their impacts on health care system and their cost effectiveness. |
| Qualigenics Diabetes Centre & CardioMed Heart Centre | |
| Contact
person: Dr. Norman Chan, Clinical Director Tel no : 852 3607 7800 Fax no 852 2868 6849 website: http://www.qualigenics.com |
|
Qualigenics
Diabetes Centre was open in October 2002 as a technology transfer of
CUHK to GenRx, a subsidiary of HKR International, a public listed company
which funds the project entirely. This academic-industrial collaboration
aims to develop Qualigenics into a Medical Centre of Excellence in China
and Asia by creating a platform to promote sharing of best practices
focusing on disease prevention and education using a multidisciplinary
approach, targeting particularly at patients with chronic diseases,
notably, diabetes, obesity and heart disease.
Qualigenics has 2 Centres, one based at the CUHK School of Public Health located on the PWH Campus and the other at the Pier 3, Central District (opposite to International Financial Centre). In April 2005, to further increase the scope and quality of services provided at the Centre, CardioMed Heart Centre was formed under Qualigenics and is based at the Pier 3 Centre. Together, the 2 Centres employ a team of 22 members including endocrinologists, cardiologists, diabetes educators, pharmacists, nurses, physical trainers, dietitians, administrators and marketing personnel to provide a range of quality assured, convenient and affordable health care services through collaboration with other medical practitioners and health care workers in the community. |
|
| Diabetes, Endocrinology and Clinical Pharmacology Centre (DECP) | |
| Head:
Professor Juliana Chan Tel number: 852 2632 3663 Fax number: 852 2632 3108 |
|
| Research Nurses: | |
| Ms Cherry Chiu (Nursing Officer), Ms Yee Mui Lee, Ms Delanda Wong, Ms Athena Hong, Ms Lena Lam, Ms Ada Chong,Ms Jennifer Tiu, Ms Lap Yin Ho, Ms Cindy Yuen, Ms Emily Yu | |
| Research Assistants: | |
Ms
Daphne Cheung, Ms Carrie Wong, Ms Alice Au, Ms Edith Kwok. |
|
| Secretary: | |
| Ms. Sinwah Cheng | |
| The forerunners
of DECP were the PWH Metabolic Investigation Unit established in 1985
by Professor Clive Cockram, Clinical Pharmacology Study Unit in 1989 by
late Professor Julian Critchley and Novo Nordisk Clinical Trial Centre
in 2001 by Dr. CC Chow.
Since early 1990s, members of these centres have conducted more than 30 phase 1-4 clinical trials in diabetes, hypertension and metabolic syndrome in accordance to Good Clinical Practice supported by a large number of multinational companies. The DECP is now fully equipped to initiate, conduct and coordinate major studies in the field of diabetes, metabolic syndrome and endocrinology while at the same time provide the best of care to these patients under a structured protocol delivered by dedicated personnel. The Centre employs 4 doctors engaged mainly in clinical research, further supported by a team of dedicated and highly experienced research nurses and personnel. The Centre works in close partnership with the CUHK Centre for Clinical Trials and the CUHK Drug Development Centre to examine the safety, efficacy and tolerability of novel compounds as well as to evaluate their therapeutic potentials by conducting proof of concept studies for new indications. Senior members of the Centre are often members of the steering committee of landmark studies or members of advisory boards of novel compounds. The Centre has been inspected by the headquarters of major pharmaceutical companies including Novo Nordisk, MSD, Astra Zeneca and Sankyo as well as US-FDA and its equivalent in Japan. |
|
| Research Interests | |
| 1. | Applied genomics and bioinformatics with particular focus on young onset diabetes and diabetic kidney disease in Chinese |
| 2. | Clinical trials to examine the efficacy and tolerability of novel drugs for the treatment of diabetes, obesity and its complications |
| 3. | Clinical epidemiology and outcome research in diabetes including the development of various risk engines and cost-effective analysis of various drugs and health care programs |
| 4. | Drug discovery and cell replacement including the scientific evaluation of TCM and use of stem cells to develop beta cells for mechanistic studies and clinical development |
| Selected Publications | |
| 1. | Tong PCY, Ho CS, Yeung VTF, Ng MCY, So WY, Ozaki R, Ko GTC, Ma RCW, Poon E, Chan NN, Lam CWK, Chan JCN. Low testosterone and insulin-like growth factor-1 but high C-reactive protein are independent predictors for metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2005 (on line and in press). |
| 2. | Wang Y, Ng MCY, So WY, Tong PCY, Ma RCW, Chow CC, Cockram CS, Chan JCN. Prognostic effect of insertion/deletion polymorphism of the ACE gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care. 2004;28:348-54. |
| 3. | Leung WYS, So WY, Tong PCY, Chan JCN. The effects of a pharmacist-diabetologist managed diabetic nephropathy clinic reduces new onset of end stage of renal disease. American Journal of Medicine 2005:in press. |
| 4. | Ng MC, So WY, Cox NJ, Lam VK, Cockram CS, Critchley JA, Bell GI, Chan JCN. Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 2004;53:1609-13. |
| 5. | Zhao HL, Tong PCY, Lai FM, Tomlinson B, Chan JCN. Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. Diabetes. 2005;53:2984-91. |
| 6. | Ng MCY, So WY, Lam VK, Cockram CS, Bell GI, Cox NJ, Chan JCN. Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 2004;53:2676-83. |
| 7. | Tong PCY, Lee KF, So WY, Ng MH, Chan WB, Lo MK, Chan NN, Chan JCN. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004;27:216-22. |
| 8. | Chan JCN, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Reduction In Endpoints in NIDDM with Angiotensin II Antagonist Lostartan Study Investigators. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. Diabetes Care 2004;27:874-9. |
| 9. | Chan JCN, Cheung JCK, Stehouwer CDA, Emeis JJ, Tong PCY, Ko GTC, Yudkin JS. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome - an analysis by structural equation modelling. International Journal of Obesity 2002;26:994-1008. |
| 10. | Chow, CC, Sorensen JP, Tsang LWW et al. Comparison of Insulin with or without continuation of oral hypoglycaemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-314. |
